PulmonologyNews.net

Pulmonology Xagena

Search results for "Idiopathic pulmonary fibrosis"

A research has shown that idiopathic interstitial pneumonia ( IIP ), a group of potentially fatal disorders that affects the lungs, may be caused by an interaction between a specific genetic backgroun ...


Abnormal acid gastro-oesophageal reflux is common in patients with idiopathic pulmonary fibrosis ( IPF ) and is considered a risk factor for development of IPF. Retrospective studies have shown improv ...


The clinical features of idiopathic pulmonary fibrosis ( IPF ) and chronic hypersensitivity pneumonitis can be indistinguishable; the need to eliminate occult environmental factors known to cause pulm ...


Nintedanib is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of Nintedanib twice daily reduced lung-function decline and acute ...


Acetylcysteine has been suggested as a beneficial treatment for idiopathic pulmonary fibrosis, although data from placebo-controlled studies are lacking. In the initial double-blind, placebo-contro ...


Present guidelines for the diagnosis of idiopathic pulmonary fibrosis require histological confirmation of surgical lung biopsy samples when high-resolution CT images are not definitive for usual inte ...


A pre-specified subgroup analysis from the two replicate Phase III INPULSIS trials, presented at the European Respiratory Society International Congress ( ERS ), has shown Nintedanib slowed disease pr ...


The double blind, randomised and placebo-controlled IMPULSIS trials, involving 1,066 patients across 24 countries, evaluated the effect of oral Nintedanib 150 mg twice daily, on the annual rate of dec ...


The FDA ( Food and Drug Administration ) has approved Ofev ( Nintedanib ) for the treatment of idiopathic pulmonary fibrosis ( IPF ), a debilitating and fatal lung disease, which has a median survival ...


Pirfenidone ( Esbriet ) is a novel antifibrotic drug for the treatment of mild-to-moderate idiopathic pulmonary fibrosis ( IPF ). However, adverse events may offset treatment benefits and compliance. ...


In the two replicate, placebo-controlled, 52-week, phase III INPULSIS trials, Nintedanib ( Ofev ) 150 mg twice daily significantly reduced the annual rate of decline in forced vital capacity ( FVC ), ...


Idiopathic pulmonary fibrosis ( IPF ) is a progressive disease characterised by dyspnea and loss of lung function. Using pooled data from the replicate, randomized, 52-week, placebo-controlled INPU ...


Idiopathic pulmonary fibrosis ( IPF ) is a progressive diffuse lung disease associated with an increased risk of lung cancer. Patients with idiopathic pulmonary fibrosis sometimes develop a life-threa ...


Idiopathic pulmonary fibrosis ( IPF ) is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause occurring in adults. Radiologic and/or histopathologic patterns are ...


Studies have suggested a procoagulant state may be involved in promoting fibrosis via cell-surface receptor–mediated pathways providing biological plausibility for a mechanistic link between thrombosi ...